We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.

CSL, in contrast, has stagnated for five years, underperforming the ASX200 by 22% in the past year. Its latest earnings miss ...

Welcome to the second weekly report for the February 2025 results season. The FNArena Reporting Season Monitor reports ...

When it comes to investing in gold, many investors are faced with a choice: physical gold or gold mining stocks. While both ...

Yarra Capital's Roy Keenan is a fixed income tragic, with 40+ years in the chair. Here, he shares his take on today's key ...

A new year with old themes. Strong absolute returns and the stocks which have benefited most from multiple divergence in 2024 ...

AI is a long-term growth story which will support the global economy and provide a wide range of potential investment ...

Its impact upon stocks – and of stocks upon it – has long been scant. Investors should ignore it and those who try to predict its actions.

Despite sky-high valuations, Jun Bei Liu is bullish on Pro Medicus. She first bought at $25 - now it’s 10x’d. How much higher ...

February earnings season is here, and it could be make or break for beaten down stocks in the ASX Energy sector like Woodside ...

The largest position in The Montgomery Fund portfolio, at almost eight per cent of the portfolio, is the Commonwealth Bank of ...

This earnings season could be make-or-break for ASX resources stocks as lower commodity prices and the looming trade war come ...